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COVID-19 and its implication for  
venous thromboembolism
Coronavirus disease (COVID-19) is caused 
by the novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) and is responsible 
for the ongoing 2019–2020 pandemic. Infected 
patients can be asymptomatic or show a range of 
symptoms including: fever, cough, fatigue, and 
dyspnea. These symptoms, except fever, are also 
typical for acute pulmonary embolism (APE). The 
overlapping symptoms of this diseases may result 
in under-recognition of APE.
Patients with COVID-19 infections are at an 
increased risk of thromboembolic complications. 
In hospitalized patients, a sudden deterioration 
of crucial vital parameters including tachycardia, 
hypotension, desaturation should suggest APE. Of 
note, temporary SIQIIITIII pattern in electrocar-
diogram, similar to alterations observed in APE 
was reported in COVID-19 patients [1].
Incidence of venous thromboembolism  
in patients with COVID-19
There is an increasing number of reports on 
thromboembolic complications in COVID-19 pa-
tients. Klok et al. [2] analyzed data of 184 patients 
(mean age 64 ± 12 years, 24% female) admitted 
to the intensive care unit (ICU) of Dutch hospitals 
due to proven COVID-19 pneumonia. All patients 
received at least prophylactic doses of nadroparin. 
The composite outcome was symptomatic APE, 
deep-vein thrombosis, ischemic stroke, myocardial 
infarction, or systemic arterial embolism. The 
cumulative incidence of the composite outcome 
was 31% (95% confidence interval [CI] 20–41%), 
of which computed tomography pulmonary angio-
gram and/or ultrasonography confirmed venous 
thromboembolism (VTE) in 27% (95% CI 17–37%) 
and arterial thrombotic events in 3.7% (95% CI 
0–8.2%). APE was the most frequent thrombotic 
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Interesting data come from Wuhan, China, 
published by Cui et al. [3], 81 patients (mean age 
59.9 ± 14.1 years, 54% female) with severe coro-
navirus pneumonia were enrolled. The incidence 
of VTE in these patients was 25% (20/81), of which 
8 patients with VTE events died [3]. Wichmann 
et al. [4] performed complete autopsies of the 
12 consecutive COVID-19 positive deaths. Autopsy 
revealed deep venous thrombosis in 7 of 12 pa-
tients (58%) in whom VTE was not suspected 
before death. APE was the direct cause of death 
in 4 patients [4].
In a recently published, prospective study, 
Helms et al. [5] described the COVID-19 in-
duced thrombotic complications in 150 consecutive 
COVID-19 acute respiratory distress syndrome 
patients. Despite anticoagulation 64 clinically 
relevant thrombotic complications were mainly 
diagnosed as APE (16.7%) [5].
There is also interesting data from Lombardy, 
an Italian region that was most affected by the 
pandemic. In one paper, all cases of COVID-19 in-
hospital patients undergoing duplex ultrasound for 
clinically suspected deep vein thrombosis. Of 101 
duplex ultrasounds performed, 42 were positive 
for deep vein thrombosis. Moreover, in 24 patients 
APE was diagnosed. Three patients in ICU were 
already under anticoagulant therapy, while the 
rest were receiving prophylactic dosages of low 
molecular weight heparins [6].
The available data support the high incidence 
of thromboembolic complications in COVID-19 
patients despite thromboembolism prophylaxis.
Potential mechanisms of increased VTE 
risk in COVID-19 patients
Several mechanisms in patients with COVID-19 
potentially promote the development of VTE. 
They fulfil at least two of the three criteria of 
Virchow’s triad: reduced venous flow from im-
mobility, as well as prothrombotic changes due 
to inflammatory state [7]. Vessel wall changes, 
the third criteria of Virchow’s triad, may also be 
present in infected patients Moreover, hypoxia 
in COVID-19 pneumonia subjects may also be 
a factor for increasing the risk of thromboembolic 
complications. 
Serum level of angiotensin 2 is significantly 
elevated in infected patients, activating the renin– 
–angiotensin system, which can cause widespread 
endothelial dysfunction. It is worth noting that the 
virus can bind to the endothelial cells via angioten-
sin 2 receptors — which are present mainly in the 
lungs, heart, and kidneys, followed by endothelial 
cells. This process may finally damage blood ves-
sels and increase the risk of thrombosis [8]. It 
is also possible that antiphospholipid antibodies, 
that appear transiently in critically ill patients, 
may cause an increased risk of thromboembolism. 
There is a case report of 3 critically ill patients 
with confirmed COVID-19. They presented clini-
cally significant ischemia of the lower limbs and 
multiple cerebral infarcts. Among these patients, 
antiphospholipid antibodies were detected [9].
Laboratory findings and diagnostic  
approach in patients with COVID-19
In COVID-19 patients the most typical labora-
tory findings include leukopenia, lymphocytopenia, 
mild thrombocytopenia, prolonged prothrombin 
time, increased D-dimer levels, and high fibrinogen 
level at the beginning of the disease followed by 
low fibrinogen levels in severe cases [4, 10, 11]. 
Increased values of D-dimer may be secondary to an 
infection and inflammation. Therefore, in COVID-19 
patients, the specificity of D-dimer tests in diagnos-
tics of VTE is lesser than in a healthy population. 
Disseminated intravascular coagulopathy is present 
in severe cases of SARS-CoV-2. It is recommended 
only to order diagnostic tests for pulmonary embolism 
when it is clinically suspected, however pulmonary 
embolism should be considered in differential diag-
nosis. Even if the specificity of D-dimer tests may 
be lower, it is still worthwhile following diagnostic 
algorithms starting with pre-test probability and 
D-dimer testing. This may reduce the number of 
necessary computed tomography-scan examinations 
with associated complications, as well as the associ-
ated deployment of resources and personnel for trans-
porting a patient for a computed tomography scan 
with isolation precautions. Multidetector computed 
tomographic pulmonary angiography is the method of 
choice for imaging pulmonary vasculature in patients 
with suspected APE. In hemodynamically unstable 
patients, transthoracic echocardiography may be 
a first line examination. Right ventricular overload 
and dysfunction might be sufficient to prompt im-
mediate reperfusion without further testing [12].
Lower limb compression ultrasonography 
may be useful in COVID-19 patients. Compres-
sion ultrasonography has a sensitivity > 90% and 
specificity > 95% for proximal symptomatic deep 
vein thrombosis. Compression ultrasonography 
should be a part of point of care ultrasound particu-
larly in patients with unexplained right ventricular 
dysfunction, unexplained hypoxemia or in patients 
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with suspected APE who are unable undergo fur-
ther evaluation. 
Every single physical examination, laboratory 
test, or imaging of the patients including computed 
tomographic pulmonary angiography, compression 
ultrasonography, and echocardiography, requires 
the full protection of staff. Additionally, all equip-
ment should be sterilized. 
According to the literature, an increase of 
D-dimer level correlates with an increase in hos-
pital mortality. Tang et al. [11] revealed data of 183 
consecutive patients with confirmed coronavirus 
pneumonia. The overall mortality was 11.5%. The 
non-survivors revealed significantly higher D-di-
mer levels compared to survivors (2.12 [0.77–5.27] 
vs. 0.61 [0.35–1.29] mg/mL, p < 0.001) [11].
Recently, Figliozzi et al. [13] published a meta-
nalysis included 49 studies and a total of 20,211 
patients. An increased D-dimer level was related to 
adverse combined outcome (death, severe presenta-
tion, hospitalization in ICU and/or mechanical ventila-
tion (odds ratio [OR] 4.39, 1.85–10.41, p = 0.003) and 
death (OR 4.40, 1.10–17.58, p = 0.04) [13].
Treatment of VTE patients
According to the European Society of Cardiol-
ogy (ESC) guidelines, initiation of anticoagulation 
is recommended without delay in patients with high 
or intermediate clinical probability of APE, while 
diagnostic workup is in process [12]. It is very im-
portant in COVID-19 patients among whom most 
have a high or intermediate clinical probability of 
VTE. Treatment of VTE should be conducted in 
accordance with the ESC guidelines on the basis of 
risk assessment. Hemodynamically unstable, high-
risk patients, should undergo immediate reperfu-
sion by thrombolysis. It should be noted that many 
of the patients with COVID-19 have an absolute or 
a relative contraindication to thrombolysis such as 
thrombocytopenia, disseminated intravascular coag-
ulation or a recent invasive procedure. Percutaneous 
catheter direct treatment should be considered for 
patients with high-risk APE, in whom thrombolysis 
is contraindicated or failed or for intermediate high 
risk with hemodynamic deterioration on anticoagu-
lation treatment [8].
The anticoagulation therapy for stable APE 
patients is usually low molecular weight heparin 
(LMWH) or direct oral anticoagulants (DOAC). 
Unfractionated heparin may be initially preferred 
in intermediate-high risk patients and in subjects 
with severe renal failure or extreme obesity. After 
initial heparin treatment in stable APE patients, 
DOAC is preferred. However, drug interactions be-
tween DOAC and medical treatment of COVID-19 
should be considered. Lopinavir/ritonavir inhibit 
cytochrome P450 3A4 and thus may increase the 
activity of NOAC — and therefore, the risk of 
bleeding. It should be emphasized that vitamin K 
antagonists are not recommended, except for pa-
tients with mechanical valves or antiphospholipid 
syndrome [14].
Thromboprophylaxis
Due to the increased risk of thromboembolic 
complications in patients with COVID-19, Interna-
tional Society on Thrombosis and Hemostasis (ISTH) 
and American Society of Hematology (ASH) guide-
lines advise prophylactic LMWH in all hospitalized 
COVID-19 patients in the absence of any contrain-
dications [15, 16]. Therefore, thromboprophylaxis 
should be considered in all hospitalized patients due 
to COVID-19. Some authors recommended consider-
ing higher prophylactic doses of anticoagulation such 
as enoxaparin 0.5 mg/kg b.i.d. or 1 mg/kg once daily 
[2, 7]. Similar, according to CHEST Guideline and 
Expert Panel Report all hospitalized patients with 
COVID-19 are at increased risk of VTE. Therefore 
experts suggest against individualized VTE risk as-
sessment and suggest anticoagulant thromboprophy-
laxis in all hospitalized patients with COVID-19 in the 
absence of contraindication [17]. Only a few papers 
address the issue of extended duration prophylaxis. 
Post discharge VTE and major bleeding rates in 
COVID-19 patients are currently unknown. Most 
experts recommended against routine extended, 
post discharge, duration prophylaxis in hospitalized 
patients, although an individualized approach for each 
patient should be considered [17].
Conclusions
Patients with COVID-19 infections are at 
increased risk of thromboembolic complications, 
a potentially preventable cause of death. Hospital-
ized patients should receive VTE prophylaxis. The 
diagnostic approach should be carried out accord-
ing to the ESC guidelines, but physicians must be 
aware of the lower specificity of the D-dimer test. 
Every single physical examination, laboratory 
test, and imaging requires the full protection of 
staff. The anticoagulation therapy for stable VTE 
patients is usually LMWH or DOAC; vitamin K 
antagonists are not recommended.
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